A trial of decitabine and ECF chemotherapy for advanced stomach cancer

Cancer type:

Stomach cancer

Status:

Results

Phase:

Phase 1

This trial was looking at a drug called decitabine in combination with ECF chemotherapy for advanced stomach cancer.

Doctors often treat cancer of the stomach (gastric cancer) with chemotherapy and surgery. One of the most common types of chemotherapy for stomach cancer is a combination of drugs called ECF. This is epirubicin, cisplatin and fluorouracil (5FU).

In this trial, doctors wanted to see if another drug called decitabine made ECF work better. Decitabine works by changing the activity of some of the genes in the cancer cells. This may make the cells more sensitive to ECF. Doctors hoped that adding this new drug would make ECF more effective.

The aims of the trial were to find out

  • The best dose of decitabine to give
  • What the side effects were
  • How well decitabine and ECF worked together

Summary of results

Despite attempting to contact the trial team, we have been unable to get any results for this trial.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Mark Middleton

Supported by

Experimental Cancer Medicine Centre (ECMC)
MGI Pharma Inc

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 739

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page